The report covers forecast and analysis for the monoclonal antibody therapeutics market on a global and regional level. The study provides historic data of 2015 to 2017 along with a forecast from 2018 to 2023 based on revenue (USD Billion). The study includes drivers and restraints for the monoclonal antibody therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the monoclonal antibody therapeutics market on a global level.


In order to give the users of this report a comprehensive view on the monoclonal antibody therapeutics market, we have included a competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.


The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions mergers, new product launch, agreements, partnerships, collaborations joint ventures, research development, product and regional expansion of major participants involved in the market.



The study provides a decisive view on the monoclonal antibody therapeutics market by segmenting the market based on application, source, end user and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2023. Based on application, the market is segmented into cancer, autoimmune diseases, infection, hematological diseases, and others. By source, the market is segmented into human, humanized, chimeric and others. Based on end users, the market is segmented into hospitals, private clinics and research institutes. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East Africa with its further bifurcation into major countries including the U.S., UK, Germany, France, China, Japan, India, Brazil, etc. This segmentation includes demand for monoclonal antibody therapeutics market based on all segments in all the regions and countries.


The report also includes detailed profiles of end players such as Pfizer Inc., Bayer AG, Sanofi, Merck Co., Inc., GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Novartis AG, and AbbVie Inc.


This report segments the global monoclonal antibody therapeutics market as follows:


Global Monoclonal Antibody Therapeutics Market: Application Segment Analysis

Cancer

Autoimmune Diseases

Infection

Hematological Diseases

Others

Global Monoclonal Antibody Therapeutics Market: Source Segment Analysis

Human

Humanized

Chimeric

Others

Global Monoclonal Antibody Therapeutics Market: End User Segment Analysis

Hospitals

Private Clinics

Research Institute

Global Monoclonal Antibody Therapeutics Market: Regional Segment Analysis

North America


U.S.

Europe


UK

France

Germany

Asia Pacific


China

Japan

India

Latin America


Brazil

Middle East and Africa